Amgen, Allergan say their Avastin biosimilar showing positive results
Amgen Inc. and Allergan plc said their biosimilar candidate to treat lung cancer has shown positive results in a late-stage study that brings it one step towards coming to market as a competitor to Roche AG's Avastin.
Thousand Oaks-based Amgen(Nasdaq: AMGN) and Irvine-based Allergan(NYSE: AGN) said their drug candidate, ABP 215, has shown to be as effective as Avastin in shrinking tumors and improving survival rates among patients with advanced non-small cell lung cancer.
Avastin is Roche's best-selling…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Source Type: news
More News: Allergy | Avastin | Biotechnology | Cancer | Cancer & Oncology | Health | Health Management | Lung Cancer | Non-Small Cell Lung Cancer | Study